Zegui Tu
Overview
Explore the profile of Zegui Tu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
37
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen J, Li C, Yu Y, Liu S, Hu Q, Cai C, et al.
Cancer Epidemiol
. 2025 Feb;
95:102760.
PMID: 39904714
Background: Despite most patients with trachea, bronchus, and lung (TBL) cancer being elderly, epidemiological data specific to this population remain scarce. This study aims to update and delineate the global...
2.
Tu Z, Liao S, Chen C, Li C, Hu Q, Cai C, et al.
Cancer Commun (Lond)
. 2024 Oct;
44(12):1418-1421.
PMID: 39422330
No abstract available.
3.
Wang L, Wu Y, Kang K, Zhang X, Luo R, Tu Z, et al.
Transl Lung Cancer Res
. 2024 Jun;
13(5):1032-1046.
PMID: 38854937
Background: Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors have shown significant activity against several solid tumors by reducing the phosphorylation of the canonical CDK4/6 substrate retinoblastoma (Rb) protein, while the...
4.
Tu Z, Yu Y, Tian T, Li C, Luo J
Heliyon
. 2023 Oct;
9(10):e20465.
PMID: 37790972
Background: Our study aimed to build a risk stratification system predicting the progression-free survival (PFS) to classify patients into diverse prognostic subgroups for advanced non-small-cell lung cancer patients treated with...
5.
Tu Z, Li C, Hu Q, Luo J
J Cancer Res Clin Oncol
. 2023 Feb;
149(9):6455-6465.
PMID: 36763172
Background: Patients with laryngeal cancer have more than five times the incidence of suicide compared with the general population. In this study, we aimed to develop an online risk stratification...
6.
Yu Y, Yu M, Li Y, Zhou X, Tian T, Du Y, et al.
Front Oncol
. 2022 Sep;
12:945620.
PMID: 36059688
gene has been identified as an oncogenic driver and a potential target in various malignancies. fusions are one subtype of alterations with a rare frequency. Here, we first report a...
7.
Luo J, Hu Q, Gou M, Liu X, Qin Y, Zhu J, et al.
Front Oncol
. 2021 Oct;
11:680402.
PMID: 34660263
Background: Microtubule-associated proteins (MAPs) have been considered to play significant roles in the tumor evolution of non-small cell lung cancer (NSCLC). Nevertheless, mRNA transcription levels and prognostic value of distinct...
8.
Tu Z, Li C, Tian T, Chen Q
Lung Cancer
. 2021 Sep;
161:114-121.
PMID: 34583219
Background: This study aims to formulate a risk classification system predicting the cancer-specific survival (CSS) for postoperative stage IB NSCLC patients without lymphovascular (LVI) and visceral pleural (VPI) invasion to...
9.
Tu Z, Tian T, Chen Q, Li C
J Oncol
. 2021 Aug;
2021:8052752.
PMID: 34335761
Background: Adjuvant chemotherapy (ACT) can improve prognosis for stages II-IIIA patients with non-small-cell lung cancer (NSCLC), but its implication in stage I patients is still an intractable puzzle. This study...
10.
Tu Z, Chen X, Tian T, Chen G, Huang M
Aging (Albany NY)
. 2021 Mar;
13(5):7397-7415.
PMID: 33658396
In this study, we used public databases to investigate the prognostic significance of epigenetic regulatory gene expression in patients with non small-cell lung cancer (NSCLC). Oncomine database analysis showed that...